Pharmaceutical

Biogen’s Friedreich’s ataxia treatment authorised in UK

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Apr 24, 2025 - 06:00
Biogen’s Friedreich’s ataxia treatment authorised in UK
Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.
Read the original article

Tags:

Previous Article

Microbial Metabolite Triggers Ageing Blood Disorders

Next Article

Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Panbela obtains rights to develop and commercialise Flynpovi to treat FAP

Panbela obtains rights to develop and commercialise Fly...

Apr 12, 2023

STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case

STAT+: Was CAR-T therapy a bystander or driver of lymph...

Dec 9, 2023

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

J&J asserts its place in atopic dermatitis space with Y...

Jul 12, 2024